Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7763505 in Healthy Participants and Patients With Stable Coronary Artery Disease
NCT07495813Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of selnoflast in coronary artery disease (CAD) (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events at 6 weeks and Plasma Concentration of RO7763505 in Fasted and fed State at 3 weeks. Started Mar 2026; status: active, not recruiting.
02
Drugs
selnoflast
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07495813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495813.